Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Norihito Ohi

Motohiro Soejima

Toshihiko Kaneko

Nobuaki Sato

Kenzo Muramoto

Takashi Doko

Taro Terauchi

Hiromitsu Yokohama

Naohiro Kohmura

Mark Spyvee

Seiichi Kobayashi

Hitoshi Oinuma

Kouichi Kikuchi

Ieharu Hishinuma

Heather Davis

Boris M Seletsky

Wanjun Zheng

Yimin Jiang

André Lescarbeau

Xiang-Yi Li

Bruce Decosta

Fabian Gusovsky

Marc Pesant

Ye Yao

Hidenori Seshimo

Lynda Tremblay

Jane Daun

Yan (Janet) Zhao

Richard S Clark

Tetsuya Kawahara

Fumihiro Ozaki

Kazuo Okano

Masanobu Shinoda

Hitoshi Harada

Fumiyoshi Matsuura

Atsushi Kamada

Kazuto Yamazaki

Takafumi Motoki

Eita Emori

Yoshimitsu Naoe

Sadakazu Miyashita

Hideki Yoshitomi

Shunji Kasai

Masayoshi Ohkuro

Tohru Arai

Taro Hibara

Takashi Seiki

Osamu Takenaka

Jiro Sonoda

The present invention provides compounds having formula (I): 

Deazapurines and uses thereof

As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases. The present invention provides novel compounds of general formula (I), and pharmaceutical compositions thereof, as described generally and in classes and subclasses herein, as well as methods of making and using such compounds.

The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.  Wherein Ris a C-Caromatic cyclic hydrocarbon group etc.; R, Rand Reach independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C-Calkylene group etc.; X is a single bond, or a group represented by &#x2014;CO&#x2014;NH&#x2014; or &#x2014;NH&#x2014;CO&#x2014;, etc.; and Y is a C-Ccycloalkyl group, a C-Caromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.

[object Object]

The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein Ris a C-Caromatic cyclic hydrocarbon group etc.; R, Rand Reach independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C-Calkylene group etc.; X is a single bond, or a group represented by &#x2014;CO&#x2014;NH&#x2014; or &#x2014;NH&#x2014;CO&#x2014;, etc.; and Y is a C-Ccycloalkyl group, a C-Caromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.

1H-indazole compounds

The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein Rdesignates &#x2014;(CO)&#x2014;(NR)&#x2014;(CR&#x2550;CR)&#x2014;Ar (wherein R, Rand Reach independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted Calkyl group or the like;

Pyrazole compound and medicinal composition containing the same

The present invention provides a novel fused indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein Zand Zeach independently represent a carbonyl group, a methylene group, etc.;represents a double bond or a single bond; Rrepresents a hydrogen atom, etc.; the ring A represents a benzene ring, a naphthalene ring or a 5- to 10-membered aromatic heterocyclic ring, etc.; and R, Rand Reach independently represent (1) a hydrogen atom, (2) a halogen atom, (3) a nitro group, etc.

Fused indazole compounds

The present invention provides compounds having formula (I), wherein R, R, Rand n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally 

The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.Wherein Ris a C-Caromatic cyclic hydrocarbon group etc.; R, Rand Reach independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C-Calkylene group etc.; X is a single bond, or a group represented by &#x2014;CO&#x2014;NH&#x2014; or &#x2014;NH&#x2014;CO&#x2014;, etc.; and Y is a C-Ccycloalkyl group, a C-Caromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.

1H-indazole compound

Novel carboxylic acid derivatives of general formula (I), salts of the same, esters thereof, or hydrates of them, which are useful as insulin resistance improvers; and drugs containing the derivatives as the active ingredient. In said formula, Ris hydrogen, hydroxyl, alkyl, or the like; L is a single bond, a double bond, alkylene, or the like; M is a single bond, alkylene, or the like; T is a single bond, alkylene, or the like; W is carboxyl, &#x2014;CON(R)R, or the like;represents a single or double bond; X is oxygen, alkenylene, or the like; Y is an aromatic hydrocarbon group which may contain a heteroatom, or the like; and Z is an aromatic hydrocarbon group which may contain a heteroatom.

Carboxylic acid derivatives and drugs containing the same

Benzopiperidine derivatives

Growing community of inventors

Ibaraki, Japan

Norihito Ohi